The role of device therapy in heart failure with reduced ejection fraction(HFrEF) : a narrative review

作     者：FU Bing-qi WANG Qi TAN Tong WEI Xue-biao YU Dan-qing 付冰奇;王齐;谭桐;魏学标;余丹青

作者机构：Division of CardiologyGuangdong Cardiovascular InstituteGuangdong Provincial Key Laboratory of Coronary Heart Disease PreventionGuangdong Provincial People's HospitalGuangdong Academy of Medical SciencesGuangzhou 510080China 

出 版 物：《South China Journal of Cardiology》 (岭南心血管病杂志（英文版）)

年 卷 期：2022年第23卷第3期

页      面：215-228页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by grants from Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention (No. Y0120220151) Science and Technology Projects of Guangzhou (No. 201903010097) National Natural Science Foundation of China (No. 82002014) Natural Science Foundation of Guangdong Province (No. 2021A1515010107) 

主　　题：Heart failure with reduced ejection fraction systolic heart failure Implantable cardioverter defibrillator Cardiac resynchronization therapy Cardiac resynchronization therapy-defibrillator Device therapy 

摘      要：Heart failure has gained increasing notice due to its high prevalence and mortality rate. The management for heart failure has been emphasized on the role of device therapy. Implantable cardioverter defibrillator(ICD) and cardiac resynchronization therapy(CRT) were given strong recommendation for heart failure with reduced ejection fraction(HFrEF), considering their effectiveness on preventing sudden cardiac death(SCD), improving cardiac function and benefiting survival. In this review, we explained the underlying mechanisms of disease initiation and progression in HFrEF, in order to build the connection between the pathological basis of HFrEF and the rationality of ICD and CRT on terminating ventricular arrhythmia, improving cardiac function, decreasing the rate of adverse clinical outcomes and benefiting survival. In addition, we discussed the high-quality researches with significant values on the discovery of device therapy clinical benefits, and compared the class I recommendations for device therapy in HFr EF, suggested by American Heart Association and European Society of Cardiology.